Plantar fibromatosis is a rare condition, and most newly diagnosed patients receive conservative (nonsurgical) treatments. Real-world treatment patterns suggest symptoms may persist or return, ...
Plantar fibromatosis is a progressive condition with no FDA-approved nonsurgical treatment options. Keenova is investigating collagenase clostridium histolyticum (CCH) as a potential therapy. CCH is ...
MALVERN, Pa., July 24, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today that three presentations related to plantar fibromatosis (PFI) and plantar fasciitis (PFA) will be shared during ...
DUBLIN, Sept. 21, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that data from clinical studies of collagenase clostridium histolyticum (CCH) in patients with plantar ...
Plantar fibromatosis is a progressive condition with no FDA-approved nonsurgical treatment options. With no official treatment guidelines available, Keenova and its clinical partners are working to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results